Latent Tuberculosis in Cancer Patients
Author Information
Author(s): Mortezazadeh Masoud, Karimi Mehdi, Esfandbod Mohsen, Mofidi Abbas, Hemmati Nima, Kashani Mehdi, Shirsalimi Niyousha, Seyyed Mahmoudi Seyyed Taher, Kamali Yazdi Ehsan
Primary Institution: Tehran University of Medical Sciences
Hypothesis
What is the prevalence of latent tuberculosis in cancer patients compared to non-cancer patients?
Conclusion
The study highlights the need for vigilant latent TB screening in cancer patients due to the association between larger TST sizes and increased mortality risk.
Supporting Evidence
- The prevalence of latent TB was 27.1% in cancer patients and 20.7% in non-cancer patients.
- Mortality was significantly higher in cancer patients compared to controls (42.1% vs 1.8%).
- Deceased patients exhibited a greater prevalence of latent TB (44% vs 19.3% in survivors).
- Increased size of TST was associated with higher mortality risk among cancer patients.
Takeaway
This study looked at how many cancer patients have a hidden form of tuberculosis, which can become serious. It found that cancer patients need to be checked for this infection more often.
Methodology
A case-control study conducted at Sina Hospital in Tehran, Iran, from 2012 to 2022, involving 392 patients screened for latent TB using the tuberculin skin test.
Potential Biases
Selection bias may have occurred due to strict inclusion criteria.
Limitations
The study's retrospective design and reliance on TST instead of IGRA limit generalizability and accuracy.
Participant Demographics
107 cancer patients and 285 non-cancer patients, with a mean age of 53.7 years for cancer patients.
Statistical Information
P-Value
0.176
Confidence Interval
95%CI 15.5–106.58
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website